Skip to content
The BCI Briefing

Company profileNeural interface

Gbrain지브레인

South Korea's implanted neural-interface company, with a surface array in a first clinical study.

Location
Incheon, South Korea
Class
Neural interfaceNot counted among core BCI companies.
Also known as
GBrain · Phin Array · Phin Stim
Sources last checked
5 Oct 2026

What they are building

Develops Phin Array, a thin electrode array laid on the brain's surface to find where seizures start, and Phin Stim, a wireless implant for recording and stimulation that is in preclinical development.

Interface category
Electrocorticography
Signal
Local field potentials, including high-gamma activity
Invasiveness
Invasive
Recording / stimulation
Recording and stimulation
Main use cases
Monitor, Restore

Where they are clinically

First-in-human

The first use of a device in a small number of people, focused on safety.

Human use is of Phin Array as a temporary electrode for locating seizures in people with epilepsy, which is not a BCI application. The trial approval and the start of the trial are reported by the company and by Korean trade press; we have found no registry entry and no published result.

Access today

Experimental human research

Demonstrated in a small number of research participants. Not an established treatment.

Shown in people
A surface array used as a temporary electrode to locate seizures, in a trial reported by the company and by trade press. We found no registry entry.
Still an aim
Phin Stim, a wireless implant for recording and stimulation, which is in preclinical development.
What stands in the way
The step from a temporary diagnostic array to a chronic implant.

On record here: 0 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

Gbrain is the clearest sign of implanted neural-interface work in South Korea, a country with strong EEG research and electronics manufacturing but few implant programmes. It is at the electrode-validation stage; the step from a temporary recording array to a chronic BCI is the one to watch.

Key milestones

  1. 15 Apr 2026

    Korean trade press reports that the trial in people with epilepsy is under way, that a Series C round has opened and that the company plans a technology-track listing in 2026.

    더벨 (The Bell)

  2. Dec 2024

    South Korea's MFDS approves a clinical trial of Phin Array, according to the company.

    Gbrain

  3. Jan 2024

    Manufacturing facility receives GMP certification, according to the company.

    Gbrain

IP and patents

Filings spread across 6 of the 11 layers, most often interface and electrodes (13 of 13 families) and stimulation (11).

13
patent families identified and counted as BCI
2018
earliest first filing among them
9
first filed since 2021; the latest years are incomplete
6 of 13
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: electrodes and arrays (13), stimulation (11), materials and coatings (5), packaging and hermeticity (5), closed loop (5), wireless telemetry (4). A family can carry several.

Published in: South Korea (9), United States (3), Japan (2), counted over the 13 families whose full record was read.

7 more families counted

Families found for Gbrain in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Sources

  1. 01

    Gbrain company website: development history (opens in a new tab)

    Company reportedGbrainChecked against source 4 Oct 2026

    Company website, read in machine translation. Lists the certification and trial-approval dates.

  2. 02

    Gbrain value-up: 'Korea's Neuralink' competes on technology and enters clinical trials and approval (opens in a new tab)

    Independent reporting더벨 (The Bell)15 Apr 2026Checked against source 5 Oct 2026

    Korean financial trade press, read in machine translation. Describes Phin Array as an electrode for locating seizure onset and Phin Stim as a wireless implant for recording and stimulation, and reports a trial in people with epilepsy, a Series C round and a planned listing. Gives no patient numbers and names no hospital.